Clinical Trials Logo

Refractory Acute Leukemia clinical trials

View clinical trials related to Refractory Acute Leukemia.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05029141 Active, not recruiting - Clinical trials for Acute Myeloid Leukemia

New Double Epigenetic Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Start date: September 1, 2021
Phase: Phase 2
Study type: Interventional

This study is to investigate the therapeutic efficacy and side effect of chidamide, azacitidine combined with priming HAG regimen for relapsed or refractroy acute myeloid leukemia

NCT ID: NCT04681105 Active, not recruiting - Clinical trials for Refractory Hairy Cell Leukemia

Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies

Start date: November 18, 2020
Phase: Phase 1
Study type: Interventional

This phase I trial studies the best dose and side effects of flotetuzumab for the treatment of patients with blood cancers (hematological malignancies) that have spread to other places in the body (advanced) and have come back after a period of improvement (relapsed) or does not respond to treatment (refractory). Flotetuzumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread.

NCT ID: NCT03834961 Active, not recruiting - Solid Neoplasm Clinical Trials

Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia

Start date: October 25, 2019
Phase: Phase 2
Study type: Interventional

This phase II trial studies the side effects and how well larotrectinib works in treating patients with previously untreated TRK fusion solid tumors and TRK fusion acute leukemia that has come back. Larotrectinib may stop the growth of cancer cells with TRK fusions by blocking the TRK enzymes needed for cell growth.